載入中
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
前收盤價
US$1.38
−US$0.01 · -0.72%
盤中時間採用ET。市場資料可能有所延遲。
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
日內區間
目前US$1.38
52週區間
目前US$1.38
盤中時間採用ET。市場資料可能有所延遲。
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
日內區間
目前US$1.38
52週區間
目前US$1.38
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | 6.68萬 USD | 5.78萬 USD | 3.4萬 USD |
| 毛利 | — | — | −6.68萬 USD | −5.78萬 USD | −3.4萬 USD |
| 研究與開發 | 583.3萬 USD | 1132.7萬 USD | 1838.1萬 USD | 1697.7萬 USD | 630.44萬 USD |
| 銷售、一般及管理費用 | 373.4萬 USD | 341.2萬 USD | 707.8萬 USD | 1155.6萬 USD | 603.72萬 USD |
| 營業費用 | 956.7萬 USD | 1473.9萬 USD | 2545.9萬 USD | 2853.3萬 USD | 1234.15萬 USD |
| 利息收入 | 57.2萬 USD | 79.4萬 USD | 123.5萬 USD | 35.16萬 USD | — |
| 利息支出 | — | — | — | 35.3萬 USD | 11.11萬 USD |
| 折舊和攤銷 | 7萬 USD | 5.3萬 USD | 6.7萬 USD | 5.78萬 USD | 3.4萬 USD |
| 營業利益 | −956.7萬 USD | −1473.9萬 USD | −2545.9萬 USD | −2853.3萬 USD | −1237.56萬 USD |
| 淨利 | −899.5萬 USD | −1394.5萬 USD | −2422.1萬 USD | −2764.6萬 USD | −1248.66萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
